Enhances drug manufacturing transparency by requiring drug labels to include original manufacturer information and increasing reporting frequency.
The Drug Origin Transparency Act of 2026 amends the Federal Food, Drug, and Cosmetic Act to require drug labels to include the name and place of business of the original manufacturer, any additional manufacturers, and the packer or distributor. It also mandates that drugs bear labels with the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient. The bill allows for reasonable variations in labeling requirements through regulation.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.